[et_pb_section fb_built=”1″ _builder_version=”4.16″ custom_padding=”0px|||||” global_colors_info=”{}” theme_builder_area=”post_content”][et_pb_row _builder_version=”4.16″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” min_height=”446px” global_colors_info=”{}” theme_builder_area=”post_content”][et_pb_column type=”4_4″ _builder_version=”4.16″ custom_padding=”|||” global_colors_info=”{}” custom_padding__hover=”|||” theme_builder_area=”post_content”][et_pb_text _builder_version=”4.16″ header_text_color=”#3b8dbf” background_size=”initial” background_position=”top_left” background_repeat=”repeat” global_colors_info=”{}” theme_builder_area=”post_content”]<\/p>\n
On Tuesday October 6th<\/sup><\/span> \u00a02020, Nucleix, Israel and Palex Medical, Spain organised the webinar \u201cBladder EpiCheck\u00ae, for accurate, non-invasive bladder cancer monitoring<\/strong>\u201d.<\/p>\n Prof. Dr. Fred Witjes, Professor of oncological urology at Radboud UMC Nijmegen, the Netherlands, discussed the role of the biomarkers in the follow-up of NMIBC, and then zoomed in on Bladder EpiCheck, which is used as standard of care in his hospital.<\/p>\n Three urologists from Spain (Prof. Dr. Joaqu\u00edn Carballido, Dr. Marc Serrallach and Dr. F\u00e9lix Guerrero) presented how the Bladder EpiCheck test is used in their clinical public and private practice, while Dr. David Parada, pathologist, discussed Bladder EpiCheck from the pathologist’s point of view. These presentations were given in Spanish and are subtitled into English.<\/p>\n At the end of the session, some questions from the audience were discussed.<\/p>\n [\/et_pb_text][et_pb_video src=”https:\/\/youtu.be\/H2uMlBPDFm0″ thumbnail_overlay_color=”rgba(0,0,0,0.6)” _builder_version=”4.16″ width=”70%” module_alignment=”center” global_colors_info=”{}” theme_builder_area=”post_content”][\/et_pb_video][\/et_pb_column][\/et_pb_row][et_pb_row _builder_version=”4.16″ global_colors_info=”{}” theme_builder_area=”post_content”][et_pb_column type=”4_4″ _builder_version=”4.16″ global_colors_info=”{}” theme_builder_area=”post_content”][et_pb_button button_url=”https:\/\/bcamonitor.org\/slides-brochure\/” button_text=”Download the free slide resource and brochure” button_alignment=”center” _builder_version=”4.16″ custom_button=”on” button_text_color=”#ffffff” button_bg_color=”#3b8dbf” button_border_width=”0px” global_colors_info=”{}” theme_builder_area=”post_content”][\/et_pb_button][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=”1″ _builder_version=”4.8.2″ _module_preset=”default” custom_padding=”2px||5px|||” global_module=”303″ saved_tabs=”all” global_colors_info=”{}” theme_builder_area=”post_content”][\/et_pb_section]<\/p>\n","protected":false},"excerpt":{"rendered":" On Tuesday October 6th \u00a02020, Nucleix, Israel and Palex Medical, Spain organised the webinar \u201cBladder EpiCheck\u00ae, for accurate, non-invasive bladder cancer monitoring\u201d. Prof. Dr. Fred Witjes, Professor of oncological urology at Radboud UMC Nijmegen, the Netherlands, discussed the role of the biomarkers in the follow-up of NMIBC, and then zoomed in on Bladder EpiCheck, which […]<\/p>\n","protected":false},"author":0,"featured_media":170,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_et_pb_use_builder":"on","_et_pb_old_content":"","_et_gb_content_width":"","footnotes":""},"categories":[7],"tags":[],"class_list":["post-321","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-webinar"],"_links":{"self":[{"href":"https:\/\/bcamonitor.org\/index.php?rest_route=\/wp\/v2\/posts\/321","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/bcamonitor.org\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/bcamonitor.org\/index.php?rest_route=\/wp\/v2\/types\/post"}],"replies":[{"embeddable":true,"href":"https:\/\/bcamonitor.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=321"}],"version-history":[{"count":1,"href":"https:\/\/bcamonitor.org\/index.php?rest_route=\/wp\/v2\/posts\/321\/revisions"}],"predecessor-version":[{"id":390,"href":"https:\/\/bcamonitor.org\/index.php?rest_route=\/wp\/v2\/posts\/321\/revisions\/390"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/bcamonitor.org\/index.php?rest_route=\/wp\/v2\/media\/170"}],"wp:attachment":[{"href":"https:\/\/bcamonitor.org\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=321"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/bcamonitor.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=321"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/bcamonitor.org\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=321"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}